Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
about
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.Current status of theranostics in prostate cancer.Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.It is time to move forward into the era of Theranostics.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.[177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.PSMA Theranostics: Current Status and Future Directions.Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
P2860
Q38720855-A77F99BD-FC18-4516-B1B7-2A346EEC1F31Q47158291-F0AB3F08-7DD6-41BB-8854-CBD094C63962Q47241139-AE19618C-D364-4C42-AF8F-EFEBA141FEA9Q47603267-251952C9-77D3-45E1-AD69-4A8BB8284A8CQ47705593-D99BCD26-526D-4288-918B-B34015410C79Q48107095-55D132A0-3C05-4D5C-8369-AEC9BB867C2AQ48194472-BA4C7684-AC91-4324-B1A2-D04D96B5E012Q49546570-C0A24C61-9C0D-4EC8-9467-D5156B766156Q53695831-746E2318-3793-43AF-9C55-5A0EB267EC06Q54923034-69A2613F-C69A-45DA-A226-F3F0FFC246FEQ55023828-525A3180-8CEC-41E0-9CDE-902B39F808B9Q57117099-3AD8A9B5-B1B2-42B7-8645-4E283A967014
P2860
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Overall survival and response ...... rapy using [177Lu]Lu-PSMA-617.
@en
type
label
Overall survival and response ...... rapy using [177Lu]Lu-PSMA-617.
@en
prefLabel
Overall survival and response ...... rapy using [177Lu]Lu-PSMA-617.
@en
P2093
P2860
P1476
Overall survival and response ...... erapy using [177Lu]Lu-PSMA-617
@en
P2093
Carl Schlenkhoff
Elisabeth Eppard
Hojjat Ahmadzadehfar
Markus Essler
Rolf Fimmers
Simone Wegen
Stefan Hauser
Stefan Kürpig
P2860
P2888
P304
P356
10.1007/S00259-017-3716-2
P577
2017-05-09T00:00:00Z